XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]    
Revenue $ 13,163,000 $ 0
Income tax expense (3,088,000) (3,148,000)
Exclusive License And Collaboration Agreement    
Disaggregation Of Revenue [Line Items]    
Non refundable upfront payment received 10,000,000.0  
Transaction price 12,100,000  
Fixed upfront cash payment 10,000,000.0  
Amount related to withholding tax obligations 1,100,000  
Revenue recognized 1,100,000  
Income tax expense 1,100,000  
Exclusive License And Collaboration Agreement | Maximum    
Disaggregation Of Revenue [Line Items]    
Potential development and commercial milestones yet to receive 110,000,000.0  
Asset Purchase Agreement | Cypralis Limited    
Disaggregation Of Revenue [Line Items]    
Revenue recognized 0 0
License Agreement | Waterstone Pharmaceutical HK Limited    
Disaggregation Of Revenue [Line Items]    
Revenue recognized $ 0  
Sales Revenue Net | Customer Concentration Risk | Wholesaler One    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 47.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 25.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three    
Disaggregation Of Revenue [Line Items]    
Percentage of gross revenue 23.00%  
Product Revenue, Net    
Disaggregation Of Revenue [Line Items]    
Revenue $ 1,113,000 $ 0